List of Excipients in Branded Drug LONSURF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Taiho Pharmaceutical Co Ltd	LONSURF	trifluridine and tipiracil	64842-1025	ALCOHOL
Taiho Pharmaceutical Co Ltd	LONSURF	trifluridine and tipiracil	64842-1025	BUTYL ALCOHOL
Taiho Pharmaceutical Co Ltd	LONSURF	trifluridine and tipiracil	64842-1025	HYPROMELLOSE
Taiho Pharmaceutical Co Ltd	LONSURF	trifluridine and tipiracil	64842-1025	LACTOSE MONOHYDRATE
Taiho Pharmaceutical Co Ltd	LONSURF	trifluridine and tipiracil	64842-1025	MAGNESIUM STEARATE

LONSURF Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

LONSURF is an oral, immediate-release combination of trifluridine and tipiracil hydrochloride. Its commercial opportunity for generic manufacturers and formulation developers lies less in novel drug delivery than in cost reduction, manufacturing robustness, supply security, and differentiated dosage-form development. The core product is a film-coated tablet with a relatively conventional excipient platform, which supports multiple generic formulation paths but leaves active-ingredient, method-of-use, and regulatory barriers as the primary entry risks.

What is LONSURF and which excipients does it contain?

LONSURF contains trifluridine and tipiracil hydrochloride in fixed-dose ratios of approximately 2.5:1 by weight.

Product strength	Trifluridine	Tipiracil hydrochloride
LONSURF 15/6.14 mg	15 mg	6.14 mg
LONSURF 20/8.19 mg	20 mg	8.19 mg

The labeled inactive ingredients include lactose monohydrate, pregelatinized starch, stearic acid, colloidal silicon dioxide, and magnesium stearate. The film coat contains conventional coating materials, including hypromellose, titanium dioxide, talc, and colorants. Exact excipient quantities and manufacturing parameters are not disclosed in the U.S. prescribing information.[1]

The formulation is designed for oral administration twice daily on Days 1 through 5 and Days 8 through 12 of a 28-day cycle. Patients take the tablets within one hour after completion of morning and evening meals.[1]

Why does the formulation use a conventional excipient platform?

The combination has several formulation requirements:

• Uniform distribution of two active ingredients with different dose levels.
• Adequate tablet strength at relatively low drug load.
• Reliable dissolution after food.
• Chemical and physical stability during storage.
• Control of powder segregation during blending and compression.
• Acceptable swallowability despite cytotoxic-treatment dosing.
• Reproducible exposure for a drug with dose-limiting hematologic toxicity.

Pregelatinized starch can support tablet binding and disintegration. Colloidal silicon dioxide can improve powder flow. Magnesium stearate and stearic acid provide lubrication, although excessive lubrication can slow dissolution. Lactose contributes bulk and compressibility.

For a generic developer, the key challenge is not identifying substitute excipients. It is reproducing the finished-product performance profile without creating dissolution, content-uniformity, stability, or bioequivalence problems.

What excipient strategies are available for LONSURF generics?

The most commercially realistic strategy is a Q1/Q2-aligned immediate-release tablet using the same broad excipient classes as the reference product.

Direct-compression strategy

A direct-compression formulation can reduce processing steps and improve manufacturing economics. It may use:

• Lactose or a spray-dried lactose grade as filler.
• Pregelatinized starch or microcrystalline cellulose as binder and disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or sodium stearyl fumarate as lubricant.
• Hypromellose-based film coating.

The main development risks are segregation between trifluridine and tipiracil, sensitivity to lubricant concentration, and tablet-weight variation. Blend uniformity is particularly important because the product contains two actives administered at a fixed ratio.

Wet-granulation strategy

Wet granulation can improve content uniformity and flow when the active powders have unfavorable particle-size or density profiles. It can also support higher tablet mechanical strength.

The tradeoff is greater exposure to water and heat. Developers must establish that granulation does not cause degradation, polymorphic change, or altered dissolution. Aqueous processing may be unattractive if either active ingredient or the selected salt form has limited stability under wet conditions.

Dry-granulation strategy

Roller compaction can improve flow without exposing the blend to water. It is relevant where the active ingredients have poor flow or where the manufacturing site seeks a lower-solvent process.

The principal risks are over-compaction, slower disintegration, and production of fines during milling. These effects can shift dissolution and increase tablet-weight variability.

What formulation patents protect LONSURF?

LONSURF protection is primarily associated with the trifluridine-tipiracil combination, pharmaceutical compositions, dosing regimens, and oncology uses. A generic excipient substitution does not automatically avoid these rights.

The Orange Book identifies patents and regulatory exclusivity associated with FDA-approved LONSURF indications. Orange Book entries should be reviewed by product strength, indication, patent-use code, and expiry date before filing an ANDA.[2]

Publicly reported LONSURF patent families have included U.S. patents directed to compositions containing trifluridine and tipiracil and to therapeutic use. The relevant estate has been associated with Taiho Pharmaceutical and related entities. Patent term adjustment, terminal disclaimers, pediatric extensions, and listing changes can affect the effective barrier date.

Protection category	Relevance to generic formulation
Fixed-dose trifluridine-tipiracil composition	May cover the active combination regardless of excipient selection
Pharmaceutical composition claims	May capture tablets or oral compositions using broad excipient language
Method-of-use claims	May delay approval for colorectal, gastric, gastroesophageal-junction, or combination indications
Dosing-regimen claims	Can create indication-specific or labeling restrictions
Manufacturing claims	May affect process freedom to operate even when the finished tablet differs
Product-by-process or formulation claims	Relevance depends on claim construction and prosecution history

A formulation that replaces lactose with microcrystalline cellulose may reduce risk against a narrowly drafted excipient claim. It will not necessarily avoid a broad composition claim covering trifluridine and tipiracil.

When does LONSURF lose exclusivity?

LONSURF received FDA approval in 2015 for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and relevant biologic therapy.[3] FDA expanded the label in 2019 for metastatic gastric and gastroesophageal-junction adenocarcinoma.[4] In 2023, FDA approved LONSURF with bevacizumab for previously treated metastatic colorectal cancer.[5]

Milestone	Date
Initial FDA approval	September 2015
Gastric and gastroesophageal-junction indication	February 2019
LONSURF plus bevacizumab approval	August 2023
Chemical patent baseline	Depends on applicable Orange Book patent and adjustment
Generic approval timing	Depends on patent certifications, litigation, and use-code scope

The practical generic-entry date cannot be determined from the initial 2015 approval date alone. It depends on the latest enforceable patent covering the proposed product or the indication in the proposed label. A generic applicant may seek approval before patent expiry through a Paragraph IV certification, subject to litigation and the statutory 30-month stay.

What Paragraph IV challenges and litigation affect LONSURF?

A Paragraph IV applicant must assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The patent holder can sue within 45 days, triggering a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.

For LONSURF, the principal legal exposure is likely to involve:

1. Whether a generic fixed-dose tablet infringes composition claims.
2. Whether the proposed label induces infringement of protected treatment methods.
3. Whether a carve-out can remove a patented indication while preserving approval for unpatented uses.
4. Whether the generic formulation is materially different from the reference product under the relevant claim language.
5. Whether the listed patent is enforceable after prosecution-history, obviousness, written-description, or enablement challenges.

A generic company can reduce litigation exposure through a carefully drafted label, a section viii statement for method-of-use patents, or a formulation design that avoids narrow composition limitations. Those approaches do not eliminate risk from broad active-combination claims.

How does FDA regulate generic LONSURF tablets?

A conventional generic LONSURF product would generally proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The development package would normally require:

• Pharmaceutical equivalence to the reference listed drug.
• Demonstration of bioequivalence.
• Comparable strength, dosage form, route, and active ingredients.
• Adequate stability data.
• Manufacturing controls for content uniformity and dissolution.
• Facility compliance with current good manufacturing practice.
• Appropriate patent certifications and labeling strategy.

The product is not a biologic, so biosimilar rules do not apply. The relevant pathway is generic-drug approval, not a 351(k) biosimilar application.

A 505(b)(2) strategy could be relevant for a materially changed product, such as a new dosage form, modified-release system, liquid formulation, or alternative administration route. It would be more expensive and clinically demanding than an ANDA and could face reliance and patent-certification issues.

What excipient changes can create commercial differentiation?

The strongest opportunities are operational and patient-use improvements rather than major pharmacokinetic innovation.

Lactose-free or low-lactose formulation

A lactose-free tablet could address patients with lactose intolerance and simplify procurement for institutions that avoid lactose-containing products. The commercial value is limited unless the product also provides a clear labeling or supply advantage. Any replacement must preserve dissolution, hardness, friability, stability, and bioequivalence.

Improved moisture protection

A lower-moisture formulation, high-barrier blister, or enhanced bottle system could reduce degradation risk and improve product robustness in hot and humid markets. Packaging changes may produce a more defensible product than a simple excipient substitution if they materially improve shelf life.

Smaller or easier-to-swallow tablet

Tablet-size reduction or coating optimization could improve acceptability in oncology patients who experience nausea, mucositis, dysphagia, or treatment-related fatigue. The challenge is maintaining dose uniformity and mechanical strength at the same time.

Reduced powder segregation

A formulation using engineered excipient grades, controlled particle-size distributions, or granulation could improve commercial yield and reduce batch rejection. This opportunity is especially relevant to contract manufacturers seeking reliable production at scale.

Alternative packaging

Unit-dose blister packaging could support adherence to the complex five-days-on, two-days-off regimen. Calendar packaging or cycle-specific packaging could reduce medication errors, although packaging changes must be assessed against child-resistant and stability requirements.

Fixed-dose combination with bevacizumab

LONSURF is approved with bevacizumab, but the products are administered separately. A co-pack or regimen-management kit may be commercially feasible without creating a new pharmaceutical dosage form. A single combined oral product with bevacizumab is not technically realistic because bevacizumab is an injectable monoclonal antibody.

How strong is the LONSURF patent estate?

The estate has meaningful strength because the commercial product depends on a specific active combination and approved oncology regimens. Excipient design alone is unlikely to provide a complete freedom-to-operate solution.

Patent strength is highest where claims:

• Cover the trifluridine-tipiracil combination broadly.
• Apply to oral pharmaceutical compositions without narrow excipient limitations.
• Cover the dosing schedule used in the approved label.
• Protect a commercially important indication.
• Have later expiry than the basic composition patent.

Patent strength is lower where claims depend on narrow excipient ratios, particular manufacturing steps, or a single use code that can be removed through a section viii label carve-out.

Which companies can challenge LONSURF?

Potential challengers include large generic manufacturers with oncology portfolios, regional generic companies, and specialty pharmaceutical companies that already produce oral cytotoxic products. The commercial barrier is not limited to patent risk. A challenger must also secure controlled handling, occupational-safety infrastructure, oncology distribution, and reliable active-ingredient supply.

Taiho is the originator and primary LONSURF rights holder in the United States. Servier has held commercial rights in certain territories outside Japan and the United States through licensing arrangements. Territory-specific licensing can affect the identity of the market participant, but it does not by itself determine U.S. ANDA rights.[6]

What generic launch scenarios exist for LONSURF?

Launch scenario	Commercial profile	Main risk
At-risk Paragraph IV launch	Earliest potential entry	Patent injunction, damages, litigation cost
Settlement-based entry	Predictable launch date	Revenue-sharing or delayed-entry terms
Post-expiry launch	Lower legal risk	Price erosion and crowded market
Authorized generic or licensed copy	Faster market access	Dependence on originator terms
Differentiated 505(b)(2) product	Potential premium pricing	Clinical, regulatory, and patent burden

The most attractive generic strategy is usually a high-quality, Q1/Q2-aligned tablet with superior supply reliability and a clear patent position. A novel excipient platform is valuable only if it creates measurable stability, manufacturability, adherence, or market-access benefits.

What is the commercial opportunity for LONSURF excipient suppliers?

Excipient suppliers can target the product through platform technologies rather than LONSURF-specific claims. Relevant commercial targets include:

• Direct-compression lactose grades.
• Low-moisture and co-processed excipients.
• High-functionality disintegrants.
• Lubricants with lower dissolution impact.
• Film-coating systems compatible with cytotoxic tablets.
• High-barrier blister materials.
• Excipient and process packages for content-uniformity control.

The best opportunity is to support multiple generic developers with validated excipient grades, formulation know-how, and regulatory documentation. A supplier that can demonstrate improved dissolution robustness, lower batch variability, or reduced manufacturing time has greater commercial leverage than one offering an interchangeable commodity excipient.

Key Takeaways

• LONSURF is a conventional immediate-release film-coated tablet containing trifluridine and tipiracil hydrochloride.
• Its excipient system supports direct compression, wet granulation, and dry granulation development paths.
• The main technical risks are content uniformity, segregation, dissolution, stability, and tablet-size control.
• Excipient substitution does not by itself avoid broad patents covering the active combination or treatment method.
• Generic entry depends on Orange Book patents, Paragraph IV litigation, indication carve-outs, and settlement terms.
• The product has no biosimilar pathway because it is a small-molecule drug.
• Commercial differentiation is most credible through moisture protection, lactose reduction or elimination, smaller tablets, adherence packaging, and manufacturing efficiency.
• The highest-value supplier opportunity is a regulatory-supported formulation platform that improves batch robustness and supply economics.

FAQs

Can a generic LONSURF tablet replace lactose with microcrystalline cellulose?

Yes, provided the finished product meets pharmaceutical-equivalence, bioequivalence, dissolution, stability, and manufacturing requirements. The substitution may alter patent exposure only if the relevant patent claims are narrowly limited to lactose or a specific excipient composition.

Does the LONSURF and bevacizumab combination require a new excipient formulation?

No. The approved regimen uses separate LONSURF tablets and bevacizumab administration. A co-pack may improve regimen management, but it would not create a single combined dosage form.

Is LONSURF a candidate for a liquid oral formulation?

Technically, it may be developed as a 505(b)(2) product, but the approach would require evaluation of solubility, chemical stability, dose uniformity, cytotoxic handling, preservative compatibility, and patient-use safety. It would not normally qualify as a simple ANDA formulation.

Can a generic manufacturer avoid LONSURF method-of-use patents by removing an indication?

Potentially. A section viii statement or label carve-out can be relevant when a patent covers only a specific use. It does not avoid composition patents or method claims that remain induced by the proposed label.

What is the most defensible commercial differentiation for a LONSURF generic?

The strongest near-term differentiation is a robust, size-optimized tablet combined with moisture-protective packaging and reliable oncology supply. These advantages are more commercially practical than a complex modified-release system.

References

1. U.S. Food and Drug Administration. (2023). LONSURF (trifluridine and tipiracil) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). FDA approves Lonsurf for metastatic colorectal cancer.
4. U.S. Food and Drug Administration. (2019). FDA approves Lonsurf for metastatic gastric and gastroesophageal junction adenocarcinoma.
5. U.S. Food and Drug Administration. (2023). FDA approves trifluridine/tipiracil with bevacizumab for metastatic colorectal cancer.
6. Servier. (2021). Annual report and oncology portfolio information.